A Monocentric Retrospective Study about the Correlation between Histology and Cytology of Thyroid Indeterminate Nodules Classified as TIR 3A and TIR 3B, according to 2014 Italian Consensus for Classification and Reporting of Thyroid Cytology.
Journal
Advances in medicine
ISSN: 2356-6752
Titre abrégé: Adv Med
Pays: United States
ID NLM: 101651448
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
04
2019
revised:
27
07
2019
accepted:
05
09
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
In 2014, the Italian Consensus for Classification and Reporting of Thyroid Cytology (ICCRTC) reviewed the previous cytological classification proposed in 2007 including the subdivision of TIR 3 category into low risk (TIR 3A) and high risk (TIR 3B). In Italian literature, different rates of malignancy have been correlated to these subcategories. The aim of the study is to present our experience on this subclassification for the assessment of the malignancy risk of indeterminate thyroid nodules. We correlated the subdivision into TIR 3A and TIR 3B with the histological report by highlighting the rates of malignancy detected in the two subcategories. On the one hand, we aimed to check if the groups are associated with a real and significant difference risk of malignancy. On the other hand, we evaluated the use of this subdivision in the choice of the appropriate treatment. This is a retrospective review of all the patients with an indeterminate nodule who underwent US-FNA and had surgery at ASL Città di Torino between January 2005 and May 2018. 150 patients have been analyzed for the research; 62 (41.3%) had a malignant histological report. Rates of malignancy between TIR 3A (20.8%) and TIR 3B (60.3%) were significantly different (
Sections du résumé
BACKGROUND
BACKGROUND
In 2014, the Italian Consensus for Classification and Reporting of Thyroid Cytology (ICCRTC) reviewed the previous cytological classification proposed in 2007 including the subdivision of TIR 3 category into low risk (TIR 3A) and high risk (TIR 3B). In Italian literature, different rates of malignancy have been correlated to these subcategories.
OBJECTIVES
OBJECTIVE
The aim of the study is to present our experience on this subclassification for the assessment of the malignancy risk of indeterminate thyroid nodules. We correlated the subdivision into TIR 3A and TIR 3B with the histological report by highlighting the rates of malignancy detected in the two subcategories. On the one hand, we aimed to check if the groups are associated with a real and significant difference risk of malignancy. On the other hand, we evaluated the use of this subdivision in the choice of the appropriate treatment.
STUDY DESIGN
METHODS
This is a retrospective review of all the patients with an indeterminate nodule who underwent US-FNA and had surgery at ASL Città di Torino between January 2005 and May 2018.
RESULTS
RESULTS
150 patients have been analyzed for the research; 62 (41.3%) had a malignant histological report. Rates of malignancy between TIR 3A (20.8%) and TIR 3B (60.3%) were significantly different (
Identifiants
pubmed: 31687414
doi: 10.1155/2019/3932721
pmc: PMC6800968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3932721Informations de copyright
Copyright © 2019 Francesco Quaglino et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Diagn Cytopathol. 2012 May;40(5):375-9
pubmed: 22508673
J Cytol. 2018 Jan-Mar;35(1):27-32
pubmed: 29403166
N Engl J Med. 2004 Oct 21;351(17):1764-71
pubmed: 15496625
Pathologica. 2010 Oct;102(5):405-8
pubmed: 21361121
Int J Surg. 2017 May;41 Suppl 1:S60-S64
pubmed: 28506415
Diagn Cytopathol. 2008 Jun;36(6):425-37
pubmed: 18478609
Int J Mol Sci. 2018 Feb 02;19(2):null
pubmed: 29393868
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
Eur Thyroid J. 2017 Apr;6(2):94-100
pubmed: 28589091
Cancer Control. 2017 Oct-Dec;24(5):1073274817729231
pubmed: 28975825
Acta Cytol. 1987 Sep-Oct;31(5):587-90
pubmed: 3673463
Nat Rev Endocrinol. 2016 Nov;12(11):646-653
pubmed: 27418023
Clinics (Sao Paulo). 2018 May 21;73:e576
pubmed: 29791602
Endocrine. 2019 Mar;63(3):430-438
pubmed: 30519908
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Pathol Transl Med. 2016 May;50(3):217-24
pubmed: 27077724
Lancet Oncol. 2008 Jun;9(6):543-9
pubmed: 18495537
J Endocrinol Invest. 2018 May;41(5):531-538
pubmed: 28948534
Endocrine. 2018 Apr;60(1):31-35
pubmed: 28786076
Diagn Cytopathol. 1997 Oct;17(4):239-47
pubmed: 9316777